Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?

Area of Science:

• Hepatology
• Infectious Diseases
• Virology

Background:

• Hepatitis C virus (HCV) treatment in HIV-positive individuals has significantly advanced with direct-acting antivirals (DAAs).
• Curing HCV is critical in HIV coinfection due to accelerated liver disease progression.
• DAAs have overcome limitations of older interferon-based therapies, showing high tolerability and adherence.

Purpose of the Study:

• To review the current landscape of HCV treatment in HIV-positive individuals.
• To summarize the successes and remaining challenges of DAA therapy in this population.
• To highlight areas for future research and clinical consideration.

Main Methods:

• Review of current literature on DAA treatment for HIV/HCV coinfection.
• Analysis of reported outcomes, including sustained virological response (SVR) and discontinuation rates.
• Discussion of real-world cohort data and emerging trends.

Main Results:

• DAA therapy demonstrates high efficacy and tolerability in HIV/HCV coinfected patients, with discontinuation rates below 1%.
• Sustained virological response rates are comparable to HCV monoinfected patients, leading to similar treatment recommendations.
• Some cohorts report slightly higher relapse rates in coinfected individuals, and acute HCV reinfection is a growing concern, particularly in men who have sex with men.

Conclusions:

• DAAs have revolutionized HCV treatment for coinfected individuals, achieving high cure rates.
• Despite successes, challenges remain, including managing higher relapse rates and addressing the epidemic of acute HCV reinfection.
• Individualized treatment strategies and ongoing research are necessary to optimize HCV care in the HIV-positive population.